Literature DB >> 6172950

Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type.

H Soininen, E MacDonald, M Rekonen, P J Riekkinen.   

Abstract

The possibility of disturbed dopamine and serotonin metabolism in senile dementia of Alzheimer type was studied. The basal concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) were studied in 28 patients with senile dementia of Alzheimer type and in 13 controls of similar age with no neurological disease. The concentrations of HVA were significantly reduced in the dementia patients compared to the concentrations of the controls. The values of HVA were also significantly reduced in the most severely demented patients compared to the less severely demented ones. There was a slight but statistically significant decrease in the 5-HIAA levels in the dementia patients compared to the levels of the controls. The 5-HIAA levels were reduced in the most severely demented patients compared to the controls but not when compared with the less severely demented patients. It is concluded that in severe forms of senile dementia of Alzheimer type, there is a decrease in the levels of HVA and 5-HIAA in CSF which may reflect a decreased turnover of dopamine and serotonin. Patients diagnosed as senile dementia of Alzheimer type, but with less severe symptoms, had levels of HVA and 5-HIAA similar to controls.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6172950     DOI: 10.1111/j.1600-0404.1981.tb04392.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

1.  Using Atypical Antipsychotics in Primary Care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-12

2.  Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.

Authors:  G L Corona; M L Cucchi; P Frattini; G Santagostino; S Schinelli; A Romani; A Pola; F Zerbi; F Savoldi
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

3.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

Authors:  R Crols; J Saerens; M Noppe; A Lowenthal
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

4.  Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.

Authors:  P Hartikainen; H Soininen; K J Reinikainen; J Sirviö; R Soikkeli; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 5.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

7.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.

Authors:  T Sunderland; P N Tariot; R M Cohen; P A Newhouse; A M Mellow; E A Mueller; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.

Authors:  A M Palmer; N R Sims; D M Bowen; D Neary; J Palo; J Wikstrom; A N Davison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

10.  A long-term follow-up study of cerebrospinal fluid 5-hydroxyindoleacetic acid in delirium.

Authors:  H J Koponen; U Lepola; E Leinonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.